Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 43-53 , February 2010

Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma

Received 7 July 2009 ,Revised 8 October 2009 ,Accepted 9 October 2009.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143–154
  3. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–249
  5. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225–237
  6. Bartsch H, Montesano R. Relevance of nitrosamines to human cancer. Carcinogenesis. 1984;5:1381–1393
  7. Kensler TW, Egner PA, Wang JB, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology. 2004;127:S310–S318
  8. Pang R, Tse E, Poon TP. Molecular pathways in hepatocellular carcinoma. Cancer Lett. 2006;240:157–169
  9. Ribes J, Clèries R, Esteban L, Moreno V, Bosch FX. The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol. 2008;49:233–242
  10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med. 2008;359:378–390
  12. Je Y, Schutz FAB, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and mata-analysis of clinical trials. Lancet Oncol. 2009;10:967–974
  13. Okuno M, Kojima S, Moriwaki H. Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol. 2001;16:1329–1335
  14. Kensler TW, Quian GS, Chen JG, Groopman JD. Translational strategies for cancer prevention in liver. J Natl Cancer Inst. 2003;3:321–329
  15. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol. 2008;48:380–381
  16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444
  17. Berasain C, Casillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci. 2009;1155:206–221
  18. Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene. 2006;25:3778–3786
  19. Kawanishi S, Hiraku Y, Pinlaor S, Ma N. Oxidative stress and nitrative DNA damage in animals and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol Chem. 2006;387:365–372
  20. Elsharkawy AM, Mann DA. Nuclear factor-(B and the hepatic inflammation–fibrosis–cancer axis. Hepatology. 2007;46:590–597
  21. Karin M. The I(B kinase – a bridge between inflammation and cancer. Cell Res. 2008;18:334–342
  22. Muriel P. NF-(B in liver diseases: a target for drug therapy. J Appl Toxicol. 2009;29:91–100
  23. Gius D, Spitz DR. Redox signaling in cancer biology. Antioxid Redox Signal. 2006;8:1249–1252
  24. Klaunig JE, Kamendulis LM. The oxidative stress in carcinogenesis. Annu Rev Pharmacol Toxicol. 2004;44:239–267
  25. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
  26. Khan N, Afaq F, Mukhtar H. Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal. 2008;10:475–510
  27. Ullah MF, Khan MW. Food as medicine: potential therapeutic tendencies of plant derived polyphenolic compounds. Asian Pac J Cancer Prev. 2008;9:187–196
  28. Ramos S. Cancer chemoprevention and chemotherapy: dietary polyphenols and signaling pathways. Mol Nutr Food Res. 2008;52:507–526
  29. Korkina LG, De Luca C, Kostyuk VA, Pastore S. Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr Med Chem. 2009;16:3943–3965
  30. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol. 2005;72:1439–1452
  31. Kim YS, Young MR, Bobe G, Colbum NH, Milner JA. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res. 2009;2:200–208
  32. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev. 2009;18:13–25
  33. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle. 2008;7:1020–1037
  34. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506
  35. Shankar S, Singh G, Srivastava RK. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci. 2007;12:4839–4854
  36. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res. 2009;53:115–128
  37. Vidavalur R, Otani H, Singal PK, Maulik N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp Clin Cardiol. 2006;11:217–225
  38. Presta MA, Bruyneel B, Zanella R, Kool J, Krabbe JG, Lingeman H. Determination of flavonoids and resveratrol in wine by turbulent-flow chromatography–LC–MS. Chromatographia. 2009;69:167–173
  39. Saiko P, Szakmary A, Jaeger W, Szekeres T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?. Mutat Res. 2008;658:68–94
  40. Udenigwe C, Ramprasath VR, Aluko RE, Jones PJH. Potential of resveratrol in anticancer and anti-inflammatory therapy. Nutr Rev. 2008;66:445–454
  41. Pirola L, Fröjdö S. Resveratrol: one molecule, many targets. IUBMB Life. 2008;60:323–332
  42. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009;486:95–102
  43. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220
  44. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24:2783–2840
  45. Howells LM, Moiseeva EP, Neal CP, et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin. 2007;28:1274–1304
  46. Kundu JK, Surh Y-J. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008;269:243–261
  47. Pezzuto JM. Resveratrol as an inhibitor of carcinogenesis. Pharm Biol. 2008;46:443–573
  48. Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res. 2009;2:409–418
  49. Bertelli AA, Giovanni L, Stradi R, Urisen S, Tillement JP, Bertelli A. Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drug Expt Clin Res. 1998;24:51–55
  50. Vitrac X, Desmoulière A, Brouillaud B, et al. Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci. 2003;72:2219–2233
  51. Gester S, Wuest F, Pawelke B, Bergmann R, Pietzsch J. Synthesis and biodistribution of an18 F-labelled resveratrol derivative for small animal positron emission tomography. Amino Acids. 2005;29:415–428
  52. Abd El-Mohsen M, Bayele H, Kuhnle G, et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Brit J Nutr. 2006;96:62–70
  53. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998;58:5707–5712
  54. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun. 1999;262:20–24
  55. Hebbar V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in rat liver. Life Sci. 2005;76:2299–2314
  56. Canistro D, Bonamassa B, Pozzetti L, et al. Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem Toxicol. 2009;47:454–561
  57. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflammation Allergy Drug Target. 2007;6:168–173
  58. Rubiolo JA, Mithieux G, Vega FV. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Eur J Pharmacol. 2008;591:66–72
  59. Delmas D, Jannin B, Malki MC, Latruffe N. Inhibitor effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep. 2000;7:847–852
  60. DeLėdinghen V, Monovoisin A, Neaud V, et al. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int J Oncol. 2001;19:83–88
  61. Kozuki Y, Miura Y, Yagasaki K. Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett. 2001;167:151–156
  62. Miura D, Miura Y, Yagasaki K. Resveratrol inhibits hepatoma cell invasion by suppressing gene expression on hepatocyte growth factor via its reactive oxygen species-scavenging property. Clin Exp Metas. 2004;25:445–451
  63. Zhang Q, Tang X, Oing YL, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1α and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 2005;10:1465–1474
  64. Kuo P, Chiang L, Lin C. Resveratrol-induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci. 2002;72:23–34
  65. Kim HJ, Chang EJ, Bae SJ, et al. Cytotoxic and antimutagenic stilbenes from seeds of Paeonia lactiflora. Arch Pharm Res. 2002;3:293–299
  66. Kocsis Z, Marcsek ZL, Jakab MG, Szende B, Tompa A. Chemopreventive properties of trans-resveratrol against the cytotoxicity of chloroacetanilide herbicides in vitro. Int J Hyg Environ Health. 2005;208:211–218
  67. Sun Z, Pan C, Liu H, Wang G. Anti-hepatoma activity of resveratrol in vitro. World J Gastroenterol. 2002;8:79–81
  68. Michels G, Wätjen W, Weber N, et al. Resveratrol induces apoptotic cell death in rat H4IIE hepatoma cells but necrosis in C6 glioma cells. Toxicology. 2006;225:173–182
  69. Stervbo U, Vang O, Bonnesen C. Time- and concentration-dependent effects of resveratrol in HL-60 and HepG2 cells. Cell Prolif. 2006;39:479–493
  70. Notas G, Figli A, Kampa M, Vercauteren J, Kouroumalis E, Castanas E. Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. Biochim Biophys Acta. 2006;1760:1657–1666
  71. Yu H, Pan C, Zhao S, Wang Z, Zhang H, Wu W. Resveratrol inhibits tumor necrosis factor-α-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 2008;62:366–372
  72. Yerian LM, Anders RA, Tretiakova M, Hart J. Caveolin and thrombospondin expression during hepatocellular carcinogenesis. Am J Surg Pathol. 2004;28:357–364
  73. Yang H-l, Chen W-q, Cao X, et al. Caveolin-I enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model. J Transl Med. 2009;7:22
  74. Colin D, Lancon A, Delmas D, et al. Antiproliferative activities of resveratrol and related compounds in human hepatocyte derived HepG2 cells are associated with biochemical cell disturbance revealed by fluorescence analyses. Biochimie. 2008;90:1674–1684
  75. Khan SA, Thomas CH, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–1314
  76. Roncoroni L, Elli L, Dolfini E, et al. Resveratrol inhibits cell growth in a human cholangiocarcinoma cell line. Liver Int. 2008;28:1426–1436
  77. Carbó N, Costelli P, Baccino FM, López-Soriano FJ, Argilés JM. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun. 1999;254:739–743
  78. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003;73:1393–1400
  79. Liu H-S, Pan C-E, Yang W, Liu X-M. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol. 2003;9:1474–1476
  80. Yu L, Sun Z-J, Wu SL, Pan C-E. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol. 2003;9:2341–2343
  81. Wu S-L, Sun Z-J, Yu L, Meng K-W, Qin X-L, Pan C. Effect of resveratrol and in combination with 5-FU on murine liver cancer. World J Gastroenterol. 2004;10:3048–3052
  82. Kweon S, Kim Y, Choi H. Grape extracts suppress the formation of preneoplastic foci and activity of fatty acid synthase in rat liver. Exp Mol Med. 2003;35:371–378
  83. Tharappel JC, Lehmler H-J, Srinivasan C, Robertson LW, Spear BT, Glauert HP. Effect of antioxidant phytochemicals on the hepatic tumor promoting activity of 3,3′,4,4′-tetrachlorobiphenyl (PCB-77). Food Chem Toxicol. 2008;46:3467–3474
  84. Bishayee A, Chatterjee M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted with phenobarbital. Brit J Cancer. 1995;71:1214–1220
  85. Bishayee A, Roy S, Chatterjee M. Characterization of selective induction and alteration of xenobiotic biotransforming enzymes by vanadium during diethylnitrosamine-induced chemical rat liver carcinogenesis. Oncol Res. 1999;11:41–53
  86. Bishayee A, Sarkar A, Chatterjee M. Further evidence for chemopreventive potential of β-carotene against experimental hepatocarcinogenesis: diethylnitrosamine-initiated and phenobarbital promoted hepatocarcinogenesis is prevented more effectively by β-carotene than by retinoic acid. Nutr Cancer. 2000;37:89–98
  87. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem Biol Interact. 2009;179:131–144
  88. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  89. Khanduja KL, Bhardwai A, Kaushik G. Resveratrol inhibits N-nitrodiethylamine-induced ornithine decarboxylase and cyclooxynegase in mice. J Nutr Sci Vitaminol. 2004;50:61–65
  90. Luther DL, Ohanyan V, Shamhart PE, et al. Chemopreventive doses of resveratrol do not affect cardiac function in a rodent model of hepatocellular carcinoma. Invest New Drugs, in press. doi:10.1007/S10637-009-9332-7.
  91. Juan ME, Vinardell PM, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr. 2002;132:257–260
  92. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS. Resveratrol-associated renal toxicity. Toxicol Sci. 2004;82:614–619
  93. Horn TL, Cwik MJ, Morrissey RL, et al. Ontogenicity evaluation of resveratrol in p53(±) (p53 knockout) mice. Food Chem Toxicol. 2007;45:55–63
  94. Wong YT, Gruber J, Jenner AM, et al. Elevation of oxidative-damage biomarkers during aging in F2 hybrid mice: protection by chronic oral intake of resveratrol. Free Rad Biol Med. 2009;46:799–809
  95. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol. 2009;47:2170–2182
  96. Soleas GJ, Yan J, Goldberg DM. Ultrasensitivity assay for the three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2001;757:161–172
  97. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem. 2003;36:79–87
  98. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Disp. 2004;32:1377–1382
  99. Meng X, Maliaki P, Lu H, Lee M-J, Yang CS. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 2004;52:935–942
  100. Boocock DJ, Patel KR, Faust GE, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;848:182–187
  101. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 2007;16:1246–1252
  102. Vaz-da-Silva M, Loureiro AI, Falcao A, et al. Effect of food on the pharmacokinetic profile of trans-resveratrol. Int J Clin Pharmacol Ther. 2008;46:564–570
  103. Almeida L, Vaz-da-Silva M, Falcão A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res. 2009;53:S7–S15
  104. Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005;49:495–504
  105. Zamora-Ros R, Urpí-Sardà M, Lamuela-Raventós RM, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem. 2006;52:1373–1380
  106. Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides – two novel resveratrol metabolites in human plasma. Mol Nutr Food Res. 2008;52:549–557
  107. Miksits M, Maier-Salamon A, Aust S, et al. Sulfation of resveratrol in human liver: evidence of a major role for the sulfotransferases SULT 1A1 and SULT 1E1. Xenobiotica. 2005;35:1101–1119
  108. Brill SS, Furimsky AM, Ho MN, et al. Glucuronidation of trans-resveratrol by human liver and intestinal microsomes and UGT isoforms. J Pharm Pharmacol. 2006;58:469–479
  109. Gescher AJ. Resveratrol from red grapes – pedestrian polyphenol or useful anticancer agent?. Planta Med. 2009;74:1651–1655
  110. Camont L, Cottart CH, Rhayem Y, et al. Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Anal Chim Acta. 2009;634:121–128
  111. Kundu JK, Surh Y-J. Inflammation: gearing the journey to cancer. Mutat Res. 2008;659:15–30
  112. Upham BL, Guzvić M, Scott J, et al. Inhibition of gap junctional intercellular communication and activation of mitogen-activated protein kinase by tumor-promoting organic peroxides and protection by resveratrol. Nutr Cancer. 2007;57:38–47
  113. Kim JH, Lee BK, Lee KW, Lee HJ. Resveratrol counteracts gallic acid-induced down-regulation of gap-junction intercellular communication. J Nutr Biochem. 2009;20:149–154
  114. Cucciolla V, Borriello A, Oliva A, Galletti P, Zappia V, Della Ragione F. Resveratrol: from basic science to the clinic. Cell Cycle. 2007;6:2495–2510
  115. Francy-Guilford J, Pezzuto JM. Mechanisms of cancer chemopreventive agents: a perspective. Planta Med. 2008;74:1644–1650
  116. Miksits M, Wlcek K, Svoboda M, et al. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 2009;75:1227–1230
  117. Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′-tetramethoxystilbene (DMU-212) on adenoma development in the Apc Min/+ mouse and cycloooygenase-2 in human-derived colon cancer cells. Int J Cancer. 2005;115:194–201
  118. Lee E-O, Lee H-J, Hwang H-S, et al. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis. 2006;27:2059–2069
  119. Suh N, Paul S, Hao X, et al. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin Cancer Res. 2007;13:350–355
  120. Shibata M-A, Akao Y, Shibata E, et al. Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol. 2007;60:681–691
  121. Pan M-H, Gao J-H, Lai C-S, et al. Antitumor activity of 3,5,4(-trimethoxystilbene in COLO 205 cells and xenografts in SCID mice. Mol Carcinog. 2008;47:184–196

PII: S0305-7372(09)00155-8

doi: 10.1016/j.ctrv.2009.10.002

Cancer Treatment Reviews
Volume 36, Issue 1 , Pages 43-53 , February 2010

Article Tools

* Image Usage & Resolution